PreSep Central Venous Oximetry Catheter (ScvO2)

Continuous ScvO2 monitoring with the PreSep oximetry catheter can reveal occult tissue hypoxia that traditional vital signs can miss. The prognostic value of ScvO29 has been demonstrated in post-op high-risk surgeries,1 trauma,2 sepsis,4,5 cardiac failure in CHF3,5 and recovery in cardiac arrest6,7

Guides therapy and enables early intervention

Continuous ScvO2 is a more sensitive indicator of tissue perfusion compared to intermittent sampling and traditional vital signs alone8-10,3
Continuous ScvO2 monitoring reveals the true adequacy of tissue oxygenation, enabling early detection and assessment of clinical response to intervention8,9

Convenient, accurate and easy-to-use

The first proven triple lumen catheter with continuous ScvO2 monitoring
Designed for use with Edwards oximetry monitors such as Vigileo and optical cables

Continuous ScvO2 monitoring is also available with integrated Oligon antimicrobial†† material- which releases silver ions (Ag+) from an integrated polymer that will not wash away like antimicrobial coatings.

Protects against gram-negative and gram-positive bacteria, as well as fungi and resistant microorganism strains
Significantly reduced the catheter colonization rate in a prospective randomized trial at ten institutions versus a standard catheter11
Reduced catheter-related infections by 48% in a second study when substituted for an alternative antimicrobial catheter12

References:
1. Pearse, R, et al. Changes in central venous saturation after major surgery, and association with outcome. Crit Care 2005;9(6):R694-91. Reinhart, K, et al. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004;30(8):1572-8.
2. Scalea, TM, et al. Central venous oxygen saturation: a useful clinical tool in trauma patients. J Trauma 1990;30(12):1539-43.
3. Ander, DS, et al. Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Am J Cardiol 1998;82(7):888-91.
4. Rivers, EP, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77.
5. Rady, MY, et al. Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 1996;14(2):218-25.
6. Nakazawa, K, et al. Usefulness of central venous oxygen saturation monitoring during cardiopulmonary resuscitation. A comparative case study with end-tidal carbon dioxide monitoring. Intensive Care Med 1994;20(6):450-1.
7. Rivers, EP, et al. The clinical implications of continuous central venous oxygen saturation during human CPR. Ann Emerg Med 1992;21(9):1094-101.
8. Reinhart, K, et al. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004;30(8):1572-8.
9. Rivers, EP, et al. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care 2001;7(3):204-11.
10. Ingelmo, P, et al. Importance of monitoring in high risk surgical patients. Minerva Anestesiol 2002;68(4):226-30.
11. Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003;31(1):52-9.
12. Garcia, R, et al. Three years experience in implementing HICPAC recommendations for the reduction of central venous catheter-related bloodstream infections. Poster presentation at National APIC meeting, June 2003.

††The activity of the antimicrobial agent is localized at the catheter surfaces and is not intended for treatment of systemic infections. In vitro testing demonstrated that the Oligon material provided broad–spectrum effectiveness (≥ 3 log reduction from initial concentration within 48 hours) against the organisms tested: Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Enterococcus faecalis, Candida albicans, Escherichia coli, Serratia marcescens, Acinetobacter calcoaceticus, Corynebacterium diphtheriae, Enterobacter aerogenes, GMRSa, Pseudomonas aeruginosa, Candida glabrata and VRE (Enterococcus faecium).

Early Goal-Directed Therapy and EGDT are trademarks of Dr. Emanuel Rivers.
Oligon is a trademark of Implemed, Inc.